Stedical Scientific continues its mission to accelerate the global distribution of disruptive innovations in healthcare

CARLSBAD, Calif. and SHANGHAI, China, Nov. 02, 2022 (GLOBE NEWSWIRE) — Stedical Scientific announced today that it has secured three new billing codes, which providers may use when treating patients with PermeaDerm in the outpatient clinic and hospital outpatient department settings. The Centers for Medicare & Medicaid Services (“CMS”) approved three new Healthcare Common Procedure Coding System (“HCPCS”) codes, which became effective on October 1, 2022:

  • A2016 PermeaDerm B, per sq cm
  • A2018 PermeaDerm C, per sq cm
  • A2017 PermeaDerm Glove, each

In response to the new codes, Leo Spiegel, CEO of Stedical, stated, “We are encouraged that these new billing codes will help facilitate claims submission and, therefore, patient access to the PermeaDerm suite of products. We commend CMS on their review and decision to create new coding for PermeaDerm.”

About Stedical Scientific
Stedical Scientific (Shanghai) Co., Ltd, and its U.S.-subsidiary Stedical Scientific, Inc., based in San Diego, CA, were formed to acquire companies that focus on unmet needs and significant growth market opportunities in the healthcare field. Stedical Scientific’s mission is to expand these product portfolios of disruptive innovations and provide global marketing and distribution. Learn more at https://www.stedical.com/

CONTACT: CONTACT
Leo Spiegel, Executive Chairman 
Stedical Scientific, Inc.
lspiegel@stedical.com

Staff

Recent Posts

Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry

The ‘My Mental Health Journey’ registry is now enrolling U.S.-based adults experiencing symptoms of depression.…

2 hours ago

Primary Care Medical Partners Selects eClinicalWorks AI Solutions and Sunoh.ai to Save Time on Documentation and Reduce Physician Burnout

The advanced AI solutions and AI medical scribe will assist the practice in streamlining clinical…

2 hours ago

AlayaCare Named Preferred Home Care Technology Partner by Closing the Gap Healthcare

TORONTO, ON / ACCESSWIRE / April 4, 2024 / Closing the Gap Healthcare (CTG) announced…

2 hours ago

Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored by IAVI

The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa…

2 hours ago